USFDA Reverses Status Of Aurobindo Pharma Ltd’s General Injectable Formulation Unit

Aurobindo Pharma Ltd has announced in reference to the USFDA inspection of Unit IV, a general injectable formulation manufacturing facility of the Company, and issue of Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status by USFDA.

Today, February 21, 2020, the Company received a communication that the inspection conducted by the U.S. Food and Drug Administration (USFDA) at our aforesaid Unit IV, from November 4,2019 to November 13, 2019, is still open and under review, by way of rescindment of 90-day VAI letter that was issued by them on February 18, 2020.

Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.599.55 as compared to the previous close of Rs. 602.25. The total number of shares traded during the day was 433032 in over 9375 trades.

The stock hit an intraday high of Rs. 617 and intraday low of 590.85. The net turnover during the day was Rs. 261150445.-Equity Bulls